A phase II study of gefitinib in patients with advanced thyroid cancer.
Thyroid
; 18(3): 317-23, 2008 Mar.
Article
en En
| MEDLINE
| ID: mdl-17985985
ABSTRACT
OBJECTIVE:
To determine the efficacy of gefitinib in patients with advanced thyroid cancer.DESIGN:
In this open-label phase II trial, 27 patients with radioiodine-refractory, locally advanced, or metastatic thyroid cancer were treated with 250 mg of daily gefitinib. Histologic subtypes included papillary (41%), follicular (22%), anaplastic (19%), medullary (15%), and Hürthle cell carcinomas (4%). The primary endpoint was overall response rate. Secondary endpoints were toxicity, progression-free survival (PFS), and overall survival (OS). MAINOUTCOMES:
There were no objective responses among the 25 patients evaluated. After 3, 6, and 12 months of treatment, 48%, 24%, and 12% of patients had stable disease (SD), respectively. Median PFS and OS were 3.7 and 17.5 months, respectively. Five patients with SD had a decrease in thyroglobulin (Tg) to <90% of baseline that was maintained for at least 3 months.CONCLUSIONS:
Although gefitinib therapy did not result in any tumor responses, 32% of patients had reductions in tumor volume that did not meet criteria for partial response rate. Along with falling Tg levels and prolonged SD in a subset of patients, this may indicate biologic activity.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Quinazolinas
/
Neoplasias de la Tiroides
/
Carcinoma Papilar
/
Antineoplásicos
Límite:
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Thyroid
Asunto de la revista:
ENDOCRINOLOGIA
Año:
2008
Tipo del documento:
Article
País de afiliación:
Estados Unidos